{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:13:34Z","timestamp":1777900414886,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008250","name":"Northwestern University Feinberg School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.gore.2025.101991","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T22:15:26Z","timestamp":1763590526000},"page":"101991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A case report of total epidermal necrosis following mirvetuximab soravtansine extravasation"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4378-1682","authenticated-orcid":false,"given":"Oriana","family":"Krivenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna Scott","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connor C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia W.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Barber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2025.101991_b0005","unstructured":"Cancer Facts & Figures 2025. American Cancer Society; 2025."},{"issue":"3","key":"10.1016\/j.gore.2025.101991_b0010","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2025.101991_b0015","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab Soravtansine in FR\u03b1-Positive, Platinum-Resistant Ovarian Cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2025.101991_b0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3352\/jeehp.2020.17.21","article-title":"Guidelines for the management of extravasation","volume":"17","author":"Kim","year":"2020","journal-title":"J Educ Eval Health Prof."},{"key":"10.1016\/j.gore.2025.101991_b0025","article-title":"Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates. Eur","author":"Pipitone","year":"2025","journal-title":"J Hosp Pharm."},{"issue":"4","key":"10.1016\/j.gore.2025.101991_b0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejon.2008.07.003","article-title":"European Oncology Nursing Society extravasation guidelines","volume":"12","author":"Wengstr\u00f6m","year":"2008","journal-title":"Eur. J. Oncol. Nurs."},{"issue":"4","key":"10.1016\/j.gore.2025.101991_b0035","first-page":"198","article-title":"Classification of antineoplastic drug-induced tissue damage: a Consensus of the Spanish Oncology Pharmacy Group","volume":"45","author":"Albert-Mar\u00ed","year":"2021","journal-title":"Farm. Hosp."},{"issue":"1","key":"10.1016\/j.gore.2025.101991_b0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminoncol.2005.11.007","article-title":"Extravasation of chemotherapeutic agents: prevention and treatment","volume":"33","author":"Goolsby","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.gore.2025.101991_b0045","doi-asserted-by":"crossref","unstructured":"P\u00e9rez Fidalgo JA, Garc\u00eda Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012;23 Suppl 7:vii167-73.","DOI":"10.1093\/annonc\/mds294"},{"key":"10.1016\/j.gore.2025.101991_b0050","article-title":"The Clinical and Economic burdens of Infiltration and Extravasation with Peripheral Intravenous Catheters: a Contemporary Narrative Review. International Journal of Nursing and Health Care","author":"Amit Bahl","year":"2023","journal-title":"Research"},{"issue":"11","key":"10.1016\/j.gore.2025.101991_b0055","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.jid.2018.04.033","article-title":"Vitamin D Receptor is Required for Proliferation, Migration, and Differentiation of Epidermal Stem Cells and Progeny duringCutaneous Wound Repair","volume":"138","author":"Oda","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.gore.2025.101991_b0060","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/jbcr\/irab141","article-title":"Evaluating the Efficacy, Safety, and Tolerance of Silver Sulfadiazine Dressings once Daily Versus twice Daily in the Treatment of Burn Wounds","volume":"42","author":"Lagziel","year":"2021","journal-title":"J. Burn Care Res."},{"issue":"1","key":"10.1016\/j.gore.2025.101991_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.burns.2024.107318","article-title":"The efficacy of cellulose dressings in burn wound management: a systematic review and meta-analysis","volume":"51","author":"Hill","year":"2025","journal-title":"Burns"},{"issue":"6","key":"10.1016\/j.gore.2025.101991_b0070","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/jbcr\/iraa119","article-title":"American Burn Association guidelines on the Management of Acute Pain in the Adult Burn Patient: a Review of the Literature, a Compilation of Expert Opinion, and next steps","volume":"41","author":"Romanowski","year":"2020","journal-title":"J. Burn Care Res."},{"key":"10.1016\/j.gore.2025.101991_b0075","article-title":"Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma. Eur","author":"Rivasi","year":"2024","journal-title":"J Hosp Pharm."},{"issue":"4","key":"10.1016\/j.gore.2025.101991_b0080","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/jcpt.13148","article-title":"Extravasation of an antibody-drug conjugate: a case report of epidermal necrosis after trastuzumab-emtansine extravasation","volume":"45","author":"Sallevelt","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"issue":"7","key":"10.1016\/j.gore.2025.101991_b0085","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1177\/10781552231185505","article-title":"Drug extravasation with Enfortumab vedotin","volume":"29","author":"Grant","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.gore.2025.101991_b0090","article-title":"Adding insult to extravasation injury: recall dermatitis after extravasation injury for a novel conjugate chemotherapy","author":"Trisha Kaundinya","year":"2024","journal-title":"Northwestern Medicine"},{"issue":"8","key":"10.1016\/j.gore.2025.101991_b0095","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JOP.2016.020198","article-title":"Skin Necrosis after Ado-Trastuzumab Emtansine Extravasation","volume":"13","author":"Shafaee","year":"2017","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.gore.2025.101991_b0100","article-title":"Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer","volume":"56","author":"Son","year":"2024","journal-title":"Gynecol Oncol Rep."},{"issue":"Suppl 6","key":"10.1016\/j.gore.2025.101991_b0105","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/NAN.0000000000000144","article-title":"Eliminating Extravasation events: a Multidisciplinary Approach","volume":"38","author":"Coyle","year":"2015","journal-title":"J. Infus. Nurs."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925003169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578925003169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:30:01Z","timestamp":1777631401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578925003169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"alternative-id":["S2352578925003169"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2025.101991","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case report of total epidermal necrosis following mirvetuximab soravtansine extravasation","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2025.101991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101991"}}